AstraZeneca has rejoined the main U.S. drug lobby group, roughly two years after leaving it, the Pharmaceutical Research and ...

AstraZeneca PLC closed 24.38% short of its 52-week high of £133.88, which the company reached on September 3rd.

CEO Pascal Soriot said Europe was "falling behind" in attracting investment and needed to "invest more in what really matters ...

BNP Paribas Exane initiated coverage of AstraZeneca (AZN) with an Outperform rating and $75 price target Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter ...

Astrazeneca (AZN) ended the recent trading session at $72.72, demonstrating a -0.45% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily loss ...

New study results presented at the European Lung Cancer Congress 2025, March 26 to 29, demonstrate the role of AstraZeneca’s (AZN) TAGRISSO, as monotherapy and as the backbone for novel ...

The PMCPA has dug into the industry’s LinkedIn activities once again. AstraZeneca received the harshest censure in the latest set of cases, taking a telling-off over one of its own posts ...

Soliris (eculizumab) was first approved for paroxysmal nocturnal hemoglobinuria (PNH) in 2007 under Alexion, which later became AstraZeneca’s rare disease unit after its $39 billion buyout in 2020.

In the latest market close, Astrazeneca (AZN) reached $64.90, with a -1.35% movement compared to the previous day. The stock's change was more than the S&P 500's daily loss of 1.57%. Elsewhere ...

AstraZeneca's booth is seen during an expo in Beijing in November. The pharma company announced an investment of $2.5 billion to establish a global R&D center in Beijing. CHINA DAILY Multinational ...

Biopharmaceutical multinational AstraZeneca is not letting a bumpy 2024 dictate its path forward in China, and in the wake of a recent controversy emerges a multibillion-dollar commitment to China ...

Under the agreement, AstraZeneca will use Alteogen’s proprietary hyaluronidase platform technology to develop and commercialize subcutaneous formulations of multiple oncology assets in its portfolio.